Opendata, web and dolomites

CAN-IT-BARRIERS SIGNED

Disruption of systemic and microenvironmental barriers to immunotherapy of antigenic tumors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAN-IT-BARRIERS project word cloud

Explore the words cloud of the CAN-IT-BARRIERS project. It provides you a very rough idea of what is the project "CAN-IT-BARRIERS" about.

probe    tumor    ostensibly    dendritic    frontier    lab    types    expression    immunogenic    expanded    priori    turn    strategies    encode    immunotherapies    modalities    efficacious    oncogenes    cells    neo    microenvironment    models    systemic    corollary    therapy    cytotoxic    combined    mechanisms    therapeutic    tumors    infiltration    functional    manifestation    activation    lay    induction    presenting    cancers    antigens    antigen    papillomavirus    mouse    expansion    immune    nodes    establishing    hypothesis    genetically    producing    hpv    concert    immuno    benefit    mediated    oncogene    inhibit    cd8    barrier    solid    immunosuppressive    e6    spectrum    breaking    killing    immunosuppression    nonspecific    multiple    survival    basis    responsive    complemented    mostly    overarching    erect    unprecedented    adaptive    spleen    infiltrating    actionable    pharmacologically    marked    myeloid    groundwork    stimulatory    attack    circumvent    immunotherapy    lack    efficacy    impairing    cancer    ctls    operative    orchestrating    faceted    elicit    poorly    resistance    ll    lymph    oncoproteins    patients    refractory    human    barriers    populations    eliminating    keratinocytes    tumorigenesis    reactive    alone    lies    helping    expressing   

Project "CAN-IT-BARRIERS" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-ADG
 Funding Scheme ERC-ADG
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 2˙500˙000.00

Map

 Project objective

The frontier in cancer therapy of orchestrating the immune system to attack tumors is producing unprecedented survival benefit in some patients. The corollary is lack of efficacy both in ostensibly responsive tumor types as well as others that are mostly non-responsive. The basis lies in pre-existing and adaptive resistance mechanisms that circumvent induction of tumor-reactive cytotoxic T cells (CTLs) capable of infiltrating solid tumors and eliminating cancer cells. A priori, cancers induced by expression of human papillomavirus oncogenes should be responsive to immunotherapy: these cancers encode immunogenic neo-antigens – the oncoproteins E6/7 – necessary for their manifestation. Rather, such tumors are poorly responsive to immunotherapies. Results from my lab and others using mouse models of HPV-induced cancer have established an actionable hypothesis: during tumorigenesis, such tumors erect multiple barriers to the induction, infiltration, and killing of cancer cells by tumor antigen-reactive CTLs. These include overarching systemic antigen-nonspecific immunosuppression mediated by expanded populations of myeloid cells in spleen and lymph nodes, complemented by immune response-impairing barriers operative in the tumor microenvironment. A spectrum of models will probe these barriers, genetically and pharmacologically, establishing their functional importance, alone and in concert. A major focus will be on how oncogene-expressing keratinocytes elicit a marked expansion of immunosuppressive myeloid cells in spleen and lymph nodes, and how these myeloid cells in turn inhibit development and activation of CD8 T cells and antigen-presenting dendritic cells. Then we’ll assess the therapeutic potential of barrier-breaking strategies combined with immuno-stimulatory modalities. This project will deliver new knowledge about multi-faceted barriers to immunotherapy in these refractory cancers, helping lay the groundwork for efficacious immunotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAN-IT-BARRIERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAN-IT-BARRIERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PRIMES (2020)

Structure in the Primes, with applications

Read More  

CellProbe (2019)

CellProbe: Microfluidic probe for simultaneous tagging and extraction of single cells

Read More  

MITOvTOXO (2020)

Understanding how mitochondria compete with Toxoplasma for nutrients to defend the host cell

Read More